Research & Literature

Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.

Singh RR, Murugan P, Patel LR, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(9)):1225-35 doi:10.1038/modpathol.2015.68.

P2X7 receptor predicts postoperative cancer-specific survival of patients with clear-cell renal cell carcinoma.

Liu Z, Liu Y, Xu L, et al.

Cancer science 2015; (106(9)):1224-31 doi:10.1111/cas.12736.

Differentiation of Clear Cell Renal Cell Carcinoma From Other Subtypes and Fat-Poor Angiomyolipoma by Use of Quantitative Enhancement Measurement During Three-Phase MDCT.

Kim SH, Kim CS, Kim MJ, et al.

AJR. American journal of roentgenology 2016; (206(1)):W21-8 doi:10.2214/AJR.15.14666.

Usefulness of diffusion tensor imaging for the differentiation between low-fat angiomyolipoma and clear cell carcinoma of the kidney.

Feng Q, Ma Z, Zhang S, Wu J

SpringerPlus 2016; (5()):12 doi:10.1186/s40064-015-1627-x.

Renal Mass Biopsy: Always, Sometimes, or Never?

Kutikov A, Smaldone MC, Uzzo RG, et al.

European urology 2016; (70(3)):403-6.

[The WHO/ISUP grading system for renal carcinoma].

Moch H

Der Pathologe 2016; (37(4)):355-60 doi:10.1007/s00292-016-0171-y.

Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.

Parker WP, Cheville JC, Frank I, et al.

European urology 2017; (71(4)):665-673 doi:10.1016/j.eururo.2016.05.034.

Contemporary Treatment of Metastatic Renal Cell Carcinoma.

Stukalin I, Alimohamed N, Heng DY

Oncology reviews 2016; (10(1)):295 doi:10.4081/oncol.2016.295.

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.

Cho H, Du X, Rizzi JP, et al.

Nature 2016; (539(7627)):107-111 doi:10.1038/nature19795.

Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.

Young JR, Coy H, Kim HJ, et al.

AJR. American journal of roentgenology 2017; (208(4)):812-819 doi:10.2214/AJR.16.17152.

VEGF inhibitors in renal cell carcinoma.

Vachhani P, George S

Clinical advances in hematology & oncology : H&O 2016; (14(12)):1016-1028.

Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Identify Clear Cell Renal Cell Carcinoma in cT1a Renal Masses.

Canvasser NE, Kay FU, Xi Y, et al.

The Journal of urology 2017; (198(4)):780-786 doi:10.1016/j.juro.2017.04.089.

Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.

Dagher J, Delahunt B, Rioux-Leclercq N, et al.

Histopathology 2017; (71(6)):918-925 doi:10.1111/his.13311.

Fat status detection and histotypes differentiation in solid renal masses using Dixon technique.

Sun J, Xing Z, Chen J, et al.

Clinical imaging 2018; (51()):12-22 doi:10.1016/j.clinimag.2018.01.012.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, et al.

The New England journal of medicine 2018; (378(14)):1277-1290 doi:10.1056/NEJMoa1712126.

Generation of autochthonous mouse models of clear cell renal cell carcinoma: mouse models of renal cell carcinoma.

Hou W, Ji Z

Experimental & molecular medicine 2018; (50(4)):1-10 doi:10.1038/s12276-018-0059-4.

Follow-up after curative treatment of localised renal cell carcinoma.

Dabestani S, Marconi L, Kuusk T, Bex A

World journal of urology 2018; (36(12)):1953-1959 doi:10.1007/s00345-018-2338-z.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, et al.

The New England journal of medicine 2018; (379(5)):417-427 doi:10.1056/NEJMoa1803675.

High signal renal tumors on DWI: the diagnostic value of morphological characteristics.

Zhang H, Pan J, Shen Y, et al.

Abdominal radiology (New York) 2019; (44(1)):239-246 doi:10.1007/s00261-018-1728-4.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, et al.

European urology 2018; (74(6)):805-809 doi:10.1016/j.eururo.2018.08.008.

Grading of renal cell carcinoma.

Delahunt B, Eble JN, Egevad L, Samaratunga H

Histopathology 2019; (74(1)):4-17 doi:10.1111/his.13735.

Percutaneous renal mass biopsy: historical perspective, current status, and future considerations.

Cotta BH, Meagher MF, Bradshaw A, et al.

Expert review of anticancer therapy 2019; (19(4)):301-308 doi:10.1080/14737140.2019.1571915.

Should partial nephrectomy be considered "elective" in patients with stage 2 chronic kidney disease? A comparative analysis of functional and survival outcomes after radical and partial nephrectomy.

Hamilton ZA, Capitanio U, Lane BR, et al.

World journal of urology 2019; (37(11)):2429-2437 doi:10.1007/s00345-019-02650-9.

Benefit of nephron sparing surgery translates into lower cancer specific mortality in patients with localized renal cell carcinoma.

Mistretta FA, Mazzone E, Knipper S, Karakiewicz PI

Annals of translational medicine 2018; (6(Suppl 2)):S104 doi:10.21037/atm.2018.11.37.

Pregnancy in women known to be living with a single kidney.

Steele SE, Terry JE, Page LM, Girling JC

Obstetric medicine 2019; (12(1)):22-26 doi:10.1177/1753495X18784081.

Solitary kidney and risk of chronic kidney disease.

Kim S, Chang Y, Lee YR, et al.

European journal of epidemiology 2019; (34(9)):879-888 doi:10.1007/s10654-019-00520-7.

Prediction of significant estimated glomerular filtration rate decline after renal unit removal to aid in the clinical choice between radical and partial nephrectomy in patients with a renal mass and normal renal function.

McIntosh AG, Parker DC, Egleston BL, et al.

BJU international 2019; (124(6)):999-1005 doi:10.1111/bju.14839.

Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma.

Shirotake S, Takamatsu K, Mizuno R, et al.

Anticancer research 2019; (39(8)):4371-4377 doi:10.21873/anticanres.13606.

Palpable Abdominal Mass is a Renal Oncocytoma: Not All Large Renal Masses are Malignant.

Dey S, Noyes SL, Uddin G, Lane BR

Case reports in urology 2019; (2019()):6016870 doi:10.1155/2019/6016870.

Diagnostic performance of prospectively assigned clear cell Likelihood scores (ccLS) in small renal masses at multiparametric magnetic resonance imaging.

Johnson BA, Kim S, Steinberg RL, et al.

Urologic oncology 2019; (37(12)):941-946 doi:10.1016/j.urolonc.2019.07.023.

ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer.

, Purysko AS, Nikolaidis P, et al.

Journal of the American College of Radiology : JACR 2019; (16(11S)):S399-S416 doi:10.1016/j.jacr.2019.05.022.

Characterization of clear cell renal cell carcinoma and other renal tumors: evaluation of dual-energy CT using material-specific iodine and fat imaging.

Udare A, Walker D, Krishna S, et al.

European radiology 2020; (30(4)):2091-2102 doi:10.1007/s00330-019-06590-1.

The Roles of Cullin-2 E3 Ubiquitin Ligase Complex in Cancer.

Liu X, Zurlo G, Zhang Q

Advances in experimental medicine and biology 2020; (1217()):173-186 doi:10.1007/978-981-15-1025-0_11.

New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.

Grimm MO, Leucht K, Grünwald V, Foller S

Journal of clinical medicine 2020; (9(2)) doi:10.3390/jcm9020565.

Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis.

Obeng RC, Arnold RS, Ogan K, et al.

International journal of urology : official journal of the Japanese Urological Association 2020; (27(9)):790-797 doi:10.1111/iju.14302.

Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study.

Massari F, Di Nunno V, Guida A, et al.

Clinical genitourinary cancer 2021; (19(1)):32-40 doi:10.1016/j.clgc.2020.06.003.

The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.

Abu-Ghanem Y, Powles T, Capitanio U, et al.

European urology oncology 2021; (4(3)):473-482 doi:10.1016/j.euo.2020.09.005.

Do children with solitary or hypofunctioning kidney have the same prevalence for masked hypertension?

Yel S, Günay N, Pınarbaşı AS, et al.

Pediatric nephrology (Berlin, Germany) 2021; (36(7)):1833-1841 doi:10.1007/s00467-020-04896-7.

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Motzer R, Alekseev B, Rha SY, et al.

The New England journal of medicine 2021; (384(14)):1289-1300 doi:10.1056/NEJMoa2035716.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Choueiri TK, Powles T, Burotto M, et al.

The New England journal of medicine 2021; (384(9)):829-841 doi:10.1056/NEJMoa2026982.

Improving Renal Tumor Biopsy Prognostication With BAP1 Analyses.

Kapur P, Setoodeh S, Araj E, et al.

Archives of pathology & laboratory medicine 2022; (146(2)):154-165 doi:10.5858/arpa.2020-0413-OA.

Parallel comparison of R.E.N.A.L., PADUA, and C-index scoring systems in predicting outcomes after partial nephrectomy: A systematic review and meta-analysis.

Hu C, Sun J, Zhang Z, et al.

Cancer medicine 2021; (10(15)):5062-5077 doi:10.1002/cam4.4047.

Association of Clear Cell Likelihood Score on MRI and Growth Kinetics of Small Solid Renal Masses on Active Surveillance.

Rasmussen RG, Xi Y, Sibley RC, et al.

AJR. American journal of roentgenology 2022; (218(1)):101-110 doi:10.2214/AJR.21.25979.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, et al.

The New England journal of medicine 2021; (385(8)):683-694 doi:10.1056/NEJMoa2106391.

Cross-sectional imaging assessment of renal masses with emphasis on MRI.

Tsili AC, Moulopoulos LA, Varakarakis IM, Argyropoulou MI

Acta radiologica (Stockholm, Sweden : 1987) 2022; (63(11)):1570-1587 doi:10.1177/02841851211052999.

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma.

Grimm MO, Leucht K, Foller S

Journal of clinical medicine 2021; (10(22)) doi:10.3390/jcm10225339.

2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma.

Bedke J, Albiges L, Capitanio U, et al.

European urology 2022; (81(2)):134-137 doi:10.1016/j.eururo.2021.11.022.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Motzer RJ, Jonasch E, Agarwal N, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(1)):71-90 doi:10.6004/jnccn.2022.0001.

Risk of recurrence after nephrectomy: Comparison of predictive ability of validated risk models.

Palumbo C, Perri D, Zacchero M, et al.

Urologic oncology 2022; (40(4)):167.e1-167.e7 doi:10.1016/j.urolonc.2021.11.025.

Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups.

Sirohi D, Chipman J, Barry M, et al.

Clinical genitourinary cancer 2022; (20(3)):e233-e243 doi:10.1016/j.clgc.2022.01.005.

Belzutifan: a novel therapy for von Hippel-Lindau disease.

Zhou J, Gong K

Nature reviews. Nephrology 2022; (18(4)):205-206 doi:10.1038/s41581-022-00544-5.

Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.

Chen YW, Rini BI

Current oncology reports 2022; (24(6)):695-702 doi:10.1007/s11912-022-01196-1.

Multicenter Evaluation of Multiparametric MRI Clear Cell Likelihood Scores in Solid Indeterminate Small Renal Masses.

Schieda N, Davenport MS, Silverman SG, et al.

Radiology 2022; (303(3)):590-599 doi:10.1148/radiol.211680.

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.

Yang Y, Psutka SP, Parikh AB, et al.

Cancer medicine 2022; (11(16)):3106-3114 doi:10.1002/cam4.4679.

ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update.

, Purysko AS, Nikolaidis P, et al.

Journal of the American College of Radiology : JACR 2022; (19(5S)):S156-S174 doi:10.1016/j.jacr.2022.02.015.

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.

Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(25)):2957-2995 doi:10.1200/JCO.22.00868.

A "3S+f" Nephrometry Score System to Predict the Clinical Outcomes of Laparoscopic Nephron-Sparing Surgery.

Zhang S, Qin Z, Bi H, et al.

Frontiers in oncology 2022; (12()):922082 doi:10.3389/fonc.2022.922082.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Powles T, Tomczak P, Park SH, et al.

The Lancet. Oncology 2022; (23(9)):1133-1144 doi:10.1016/S1470-2045(22)00487-9.

Structural basis for the allosteric inhibition of hypoxia-inducible factor (HIF)-2 by belzutifan.

Ren X, Diao X, Zhuang J, Wu D

Molecular pharmacology 2022; (102(6)) doi:10.1124/molpharm.122.000525.

CD47 Expression Predicts Unfavorable Prognosis in Clear Cell Renal Cell Carcinoma after Curative Resection.

Park H, Jee S, Bang S, et al.

Diagnostics (Basel, Switzerland) 2022; (12(10)) doi:10.3390/diagnostics12102291.

Psychological Distress in Patients Treated for Renal Cell Carcinoma: A Systematic Literature Review.

Vartolomei L, Schmidinger M, Vartolomei MD, Shariat SF

Journal of clinical medicine 2022; (11(21)) doi:10.3390/jcm11216383.

Renal functional and cardiovascular outcomes of partial nephrectomy versus radical nephrectomy for renal tumors: a systematic review and meta-analysis.

Ochoa-Arvizo M, García-Campa M, Santos-Santillana KM, et al.

Urologic oncology 2023; (41(3)):113-124 doi:10.1016/j.urolonc.2022.11.024.

Clear Cell Renal Cell Carcinoma: From Biology to Treatment.

Kase AM, George DJ, Ramalingam S

Cancers 2023; (15(3)) doi:10.3390/cancers15030665.

Asymptomatic Giant Right Renal Oncocytoma: A Case Report.

Çevik G, Tozsin A, Erdoğan EG, et al.

Cureus 2023; (15(1)):e34129 doi:10.7759/cureus.34129.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

Dunsmore VJ, Neupert SD

Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

Comparison of perioperative outcomes of robotic vs. laparoscopic partial nephrectomy for renal tumors with a RENAL nephrometry score ≥7: A meta-analysis.

Jiang YL, Yu DD, Xu Y, et al.

Frontiers in surgery 2023; (10()):1138974 doi:10.3389/fsurg.2023.1138974.

Using the "2 standard deviations" rule with Dixon MRI to differentiate renal cell carcinoma types.

Sun J, Xing Z, Pan L, et al.

Clinical imaging 2023; (101()):113-120 doi:10.1016/j.clinimag.2023.06.011.

A preoperative CT-based deep learning radiomics model in predicting the stage, size, grade and necrosis score and outcome in localized clear cell renal cell carcinoma: A multicenter study.

Nie P, Liu S, Zhou R, et al.

European journal of radiology 2023; (166()):111018 doi:10.1016/j.ejrad.2023.111018.

Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities.

Cobani E, Al Hallak MN, Shields AF, et al.

Journal of gastrointestinal cancer 2024; (55(2)):519-533 doi:10.1007/s12029-023-01001-7.

Patients with high nuclear grade pT1-ccRCC are more suitable for radical nephrectomy than partial nephrectomy: a multicenter retrospective study using propensity score.

Xu H, Xing Z, Ai K, et al.

World journal of surgical oncology 2024; (22(1)):24 doi:10.1186/s12957-024-03302-y.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series.

Ercanbrack CW, Elhusseiny AM, Sanders RN, et al.

American journal of ophthalmology case reports 2024; (33()):102011 doi:10.1016/j.ajoc.2024.102011.

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma.

Hofman MS, Tran B, Feldman DR, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024; doi:10.2967/jnumed.123.267175.

Breast cancer survivorship.

Valente S, Roesch E

Journal of surgical oncology 2024; (130(1)):8-15 doi:10.1002/jso.27627.

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, et al.

The New England journal of medicine 2024; (390(15)):1359-1371 doi:10.1056/NEJMoa2312695.

Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma.

Zganjar A, Khanna A, Joyce D, et al.

The Journal of urology 2024; (212(2)):331-341 doi:10.1097/JU.0000000000004030.

Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis.

Britton CJ, Andrews JR, Wallis CJD, et al.

Urologic oncology 2023; (41(3)):125-136 doi:10.1016/j.urolonc.2022.09.021.

Clear cell likelihood score may improve diagnosis and management of renal masses.

Salles-Silva E, Lima EM, Amorim VB, et al.

Abdominal radiology (New York) 2024; (49(12)):4494-4506 doi:10.1007/s00261-024-04415-4.

Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.

Mansour H, Tran-Dang MA, Walkden M, et al.

Nature reviews. Urology 2025; (22(1)):8-25 doi:10.1038/s41585-024-00897-5.

Best predictive single nephrometry score component to correlate with achievement of trifecta outcome in laparoscopic and robotic surgery.

Suppanuntaroek S, Garcia K, Combates C, et al.

BMC urology 2024; (24(1)):134 doi:10.1186/s12894-024-01518-4.

Diagnostic accuracy of the Clear Cell Likelihood Score and selected MRI parameters in the characterization of indeterminate renal masses - a single-institution study.

Blachura T, Matusik PS, Kowal A, et al.

Abdominal radiology (New York) 2024; (49(11)):3893-3901 doi:10.1007/s00261-024-04484-5.

Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma.

Rioja P, Rey-Cardenas M, De Velasco G

Cancer treatment reviews 2024; (129()):102801 doi:10.1016/j.ctrv.2024.102801.

Comparing robotic and open partial nephrectomy under the prism of surgical precision: a meta-analysis of the average blood loss rate as a novel variable.

Artsitas S, Artsitas D, Koronaki I, et al.

Journal of robotic surgery 2024; (18(1)):313 doi:10.1007/s11701-024-02060-z.

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Choueiri TK, Powles T, Peltola K, et al.

The New England journal of medicine 2024; (391(8)):710-721 doi:10.1056/NEJMoa2313906.

Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review.

Monda S, Lara PN, Gulati S

Kidney cancer (Clifton, Va.) 2024; (8(1)):115-123 doi:10.3233/KCA-240006.

[89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.

Shuch B, Pantuck AJ, Bernhard JC, et al.

The Lancet. Oncology 2024; (25(10)):1277-1287 doi:10.1016/S1470-2045(24)00402-9.

Is fat quantification based on proton density fat fraction useful for differentiating renal tumor types?

Altay C, Başara Akın I, Özgül HA, et al.

Abdominal radiology (New York) 2025; (50(3)):1254-1265 doi:10.1007/s00261-024-04596-y.

Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in Switzerland.

Schur N, Favre-Bulle A, Flori M, et al.

Journal of medical economics 2024; (27(1)):1389-1397 doi:10.1080/13696998.2024.2417523.

RENAL Nephrometry Scores and Perioperative Outcomes in Open Partial Nephrectomy.

Nusrat NB, Kundi S, Rehman AU, et al.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024; (34(12)):1524-1529 doi:10.29271/jcpsp.2024.12.1524.

Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma.

Bedke J, Ghanem YA, Albiges L, et al.

European urology 2025; (87(4)):491-496 doi:10.1016/j.eururo.2025.01.014.

Robot-assisted partial nephrectomy for renal cell carcinoma: A narrative review of different clinical scenarios.

Grosso AA, Salamone V, Di Maida F, et al.

Asian journal of urology 2025; (12(2)):210-216 doi:10.1016/j.ajur.2024.09.010.

Surgical Strategies in Renal Cancer: A Meta-analysis of Partial vs. Radical Nephrectomy Outcomes Across Tumor Stages.

Al-Qudimat AR, Altahtamouni SB, Elaarag M, et al.

Qatar medical journal 2025; (2025(2)):54 doi:10.5339/qmj.2025.54.

Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials.

Oza B, Frangou E, Eisen T, et al.

European urology open science 2025; (79()):19-26 doi:10.1016/j.euros.2025.07.003.

Molecular and Clinicopathological Profiling of Clear Cell Renal Cell Carcinoma with Rhabdoid Features: An Integrative Pathway-Based Stratification Approach.

Lu Z, Zhao Q, Xu H, et al.

Cancers 2025; (17(17)) doi:10.3390/cancers17172744.

Diagnostic accuracy of percutaneous renal mass biopsy in patients undergoing robot-assisted partial nephrectomy for localized renal cell carcinoma.

Timane JP, Petersson RD, Jepsen RK, Thomsen FF

Urologic oncology 2025; (43(12)):708.e1-708.e6 doi:10.1016/j.urolonc.2025.09.002.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Predictors of survival after cytoreductive nephrectomy in metastatic renal cell carcinoma: A Real-world perspective.

Menon AR, Pooleri GK, Sukumaran SV, et al.

Indian journal of urology : IJU : journal of the Urological Society of India 2025; (41(4)):277-286 doi:10.4103/iju.iju_179_25.

Comparison of therapeutic effects between transabdominal robot-assisted partial nephrectomy and laparoscopic partial nephrectomy.

Zuo C, Gao Z, Gu Y

The Journal of international medical research 2025; (53(10)):3000605251390064 doi:10.1177/03000605251390064.

Comparative analysis of Robotic-Assisted, Laparoscopic, and open radical nephrectomy: Utilization, Costs, and clinical outcomes.

Huang DY, Lallas CD, Davis RM, et al.

Journal of robotic surgery 2025; (20(1)):41 doi:10.1007/s11701-025-02995-x.

Impact of obesity on peri-operative outcomes at robotic-assisted, laparoscopic and open partial nephrectomy using national inpatient sample data.

Faheem MSB, Shahabi M, Ayub A, et al.

Journal of robotic surgery 2026; (20(1)):272 doi:10.1007/s11701-026-03178-y.